Terms: = Ovarian cancer AND FES, FPS, 2242, ENSG00000182511, P07332 AND Prognosis
4 results:
1. The Application of 18 F-fes PET in Clinical cancer Care : A Systematic Review.
Huang YT; Chen TW; Chen LY; Huang YY; Lu YS
Clin Nucl Med; 2023 Sep; 48(9):785-795. PubMed ID: 37482660
[TBL] [Abstract] [Full Text] [Related]
2. Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness.
Zhang Y; Xiong X; Sun R; Zhu X; Wang C; Jiang B; Yang X; Li D; Fan G
J Biol Chem; 2023 Jun; 299(6):104825. PubMed ID: 37196766
[TBL] [Abstract] [Full Text] [Related]
3. Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia.
Oliveira T; Zhang M; Joo EJ; Abdel-Azim H; Chen CW; Yang L; Chou CH; Qin X; Chen J; Alagesan K; Almeida A; Jacob F; Packer NH; von Itzstein M; Heisterkamp N; Kolarich D
Theranostics; 2021; 11(19):9519-9537. PubMed ID: 34646384
[TBL] [Abstract] [Full Text] [Related]
4. The euploid blastocysts obtained after luteal phase stimulation show the same clinical, obstetric and perinatal outcomes as follicular phase stimulation-derived ones: a multicenter study.
Vaiarelli A; Cimadomo D; Alviggi E; Sansone A; Trabucco E; Dusi L; Buffo L; Barnocchi N; Fiorini F; Colamaria S; Giuliani M; Argento C; Rienzi L; Ubaldi FM
Hum Reprod; 2020 Nov; 35(11):2598-2608. PubMed ID: 32951051
[TBL] [Abstract] [Full Text] [Related]
